Experimental comparative study on myelotoxicity of 4'-deoxy-4'-I-doxorubicin and of doxorubicin.
4'-Deoxy-4'-I-doxorubicin (I-Dx) is 1.5-2 times more potent than doxorubicin (Dx) on some mice tumors and does not seem to be cardiotoxic. A comparison was made of the effects of both anthracyclines on mice bone marrow hemopoietic progenitors (CFU-S, GM-CFC) and peripheral blood cells. The experimental model is based on dose survival and time survival curves following single or repeated (1 weekly administration for 4 weeks) doses. Results indicate slightly higher sensitivity of assayed populations to I-DX than to Dx.